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Summary. Background: Critically ill patients with cancer are at increased risk of venous thromboembolism (VTE) from physical and cellular factors, requiring pharmacologic prophylaxis to reduce the risk of VTE. Objectives: To assess whether low-molecular-weight heparin (LMWH) prophylaxis reduces in-hospital rates of VTE or improves clinical outcomes compared with unfractionated heparin (UFH) prophylaxis in critically ill patients with cancer. Methods: We used a propensity-matched comparative-effectiveness cohort from the Premier Database. Patients aged 18 years or older with a primary diagnosis of cancer, intensive care unit admission and VTE prophylaxis within 2 days of admission between 1 January 2010 and 31 December 2014 were included. Patients were divided into LMWH or UFH prophylaxis groups. Results: A total of 103 798 patients were included; 75 321 (72.6%) patients received LMWH and 28 477 (27.4%) patients received UFH. Propensity analysis matched (2 : 1) 42 343 LMWH patients and 21 218 UFH patients. Overall, LMWH was not associated with a decreased incidence of VTE (5.32% vs. 5.50%). LMWH prophylaxis was associated with a reduction in pulmonary embolism (0.70% vs. 0.99%), significant bleeding (13.3% vs. 14.8%) and heparin-induced thrombocytopenia (HIT) (0.06% vs. 0.19%). In non-metastatic solid disease, LMWH was associated with decreased VTE (4.27% vs. 4.84%) and PE (0.47% vs. 0.95%). Conclusions: The use of an LMWH for VTE prophylaxis was not associated with a reduction in the incidence of in-hospital VTE as compared with
Introduction
Venous thromboembolism (VTE) is a common complication of critical illness associated with longer durations of mechanical ventilation, intensive care unit (ICU) length of stay and hospital length of stay [1] . Rates of deep venous thrombosis (DVT) in critically ill patients range from 13% to 31% in the absence of prophylaxis and rates of pulmonary embolism (PE) range from 7% to 27% [2] . In addition to critical illness, cancer is a significant, independent risk factor for the development of VTE, with rates of VTE reported in up to 20% of patients with cancer [3] [4] [5] . In patients with cancer, thrombosis is the second leading cause of death and is an independent prognostic factor for mortality and reduction in overall survival [3, 5, 6] . Therefore, the prevention of VTE in critically ill patients with cancer represents a major challenge in daily clinical practice.
Currently, the American College of Chest Physicians recommends the use of either low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH) therapy for the prevention of VTE in critically ill patients [7] . Pharmacologic prophylaxis in critically ill patients with UFH or LMWH reduces the risk of VTE by a range of 55-62% [8] . A recent prospective trial comparing dalteparin [Correction added on November 27, 2018 after first online publication: In a previous version of this article dalteparin was misspelled.] with UFH for VTE prophylaxis in critically ill patients found no difference in the incidences of DVT or bleeding, but did find a 1% absolute difference in PE as a secondary outcome [9] . Similar to the American College of Chest Physicians' guidelines, several leading cancer guidelines recommend the use of either LMWHs or UFH for VTE prophylaxis in hospitalized patients with reduced mobility [10] [11] [12] . Three prospective studies have compared LMWH with UFH for the prevention of VTE in non-critically ill surgical patients with cancer. These studies showed similar rates of VTE between the two treatments, with a trend toward reduced bleeding rates in the LMWH treatment [13] [14] [15] . No study has compared the efficacy and safety of LMWH and UFH therapy for the prevention of VTE in critically ill patients with cancer.
To address this gap in knowledge, we conducted a large, multicenter observational study to comparatively evaluate LMWH versus UFH in critically ill patients with cancer. We hypothesized that LMWH therapy would reduce the incidences of VTE and clinically significant bleeding events when compared with UFH prophylaxis in critically ill patients with cancer admitted to the ICU.
Methods

Data source
A pharmacologic comparative effectiveness study was designed to evaluate LMWH compared with UFH VTE prophylaxis regimens from patient data voluntarily submitted to Premier Incorporated's Perspective Database [16, 17] . This database contains patient characteristics, therapies, disease-state classifications according to the International Classification of Diseases (ICD-9) and clinical outcomes. The Colorado Multiple Institutional Review Board provided approval for the conduct of this study.
Data collection
Patients were included in this study if they were ≥ 18 years of age, were initially admitted to an intensive care unit for a minimum of 24 h between 1 January 2010 and 31 December 2014 because of a principle admitting diagnosis of lymphoma, solid tumor without metastasis, or metastatic cancer of any origin, defined by ICD-9 codes listed in Table S1 . Patients who were categorized as having either lymphoma or solid tumor without metastasis and metastatic cancer of any origin as an admitting diagnosis were categorized as metastatic cancer of any origin. Patients must have also received VTE prophylaxis within the first 48 h of admission with enoxaparin dosed 40 mg every 24 h, 30 mg every 12 h or 30 mg every 24 h, dalteparin 5000 units and 2500 units daily, fondaparinux 2.5 mg daily, or UFH 5000 units every 12 h or every 8 h. Patients were excluded if any of the following conditions were present: transferred from an outside hospital, received therapeutic intravenous anticoagulation or thrombolytic therapy within 48 h of admission, received oral anticoagulant therapy within 48 h of admission, history of heparin-induced thrombocytopenia (HIT), admission diagnosis for any VTE, admission diagnosis of major trauma, orthopedic surgical intervention during admission, neurosurgical intervention during admission, admission for a diagnosis of hemorrhage with transfusion of 2 or more packed red blood cell units, pregnancy, death within the first 48 h, or use of multiple prophylaxis regimens during hospitalization. All patients had the complete data necessary for analysis. Patients eligible for inclusion within the study were then grouped based on VTE prophylaxis regimen into either LMWH (enoxaparin dosed 40 mg every 24 h, 30 mg every 12 h or 30 mg every 24 h, dalteparin 5000 units daily, or fondaparinux 2.5 mg daily) or UFH (UFH 5000 units every 12 h or every 8 h) for comparison. Although fondaparinux is a synthetic pentassacharide rather than a true LMWH, for the purposes of this study fondaparinux has been included within the LMWH comparator group because of its longer half-life and more selective Xa inhibition, similar to LMWHs.
Outcomes
Baseline patient data, including cancer type and clinically relevant comorbidities, were collected and compared between the LMWH and UFH groups. We compared associations between patients treated with LMWH or UFH-based VTE prophylaxis and the primary composite outcome of in-hospital new-onset deep vein thrombosis or pulmonary embolism not present on admission, as defined by discharge ICD-9 codes described in Table S1 . Secondary outcomes included incidence of pulmonary embolism, in-hospital mortality, composite outcome of VTE or mortality, clinically significant bleeding events (discharge diagnosis of hemorrhage not present upon admission and/or administration of 2 or more packed red blood cell units within 24 h), incidence of HIT, ICU length of stay and hospital length of stay. All secondary outcomes were defined fields within Premier Incorporated's Perspective Database or based on discharge ICD-9 codes as defined in Table S1 . The primary and secondary outcomes were also evaluated in predefined subgroups of lymphoma, non-metastatic solid disease and metastatic disease.
Covariates
Covariates were included if they were associated with use of specific VTE prophylactic therapy. Patient-specific covariates included: age, sex, race and presence of comorbidities on admission; a full list of variables is given in Tables 1 and 2 . Treatment setting covariates included number of hospital beds, urban or rural location, major geographic area, teaching status, attending physician specialty, primary insurance status and admission year (Table 3) .
Data analysis
Patient and hospital characteristics were compared between groups using the chi-squared test for categorical data and the unpaired t-test or Kruskal-Wallis test for continuous variables as appropriate. To address the potential for selection bias between patients receiving LMWH over UFH, a propensity score for initial treatment with LMWH was developed. The dependent variable of this model was use of an LMWH and the independent covariates were the demographic, patientspecific and treatment setting factors listed in Tables 1  and 2 . The model accounted for groupings of admissions within the hospital to address confounding by indication at the patient level. A propensity-matched analysis was utilized for evaluation of primary and secondary outcomes [16, 17] . Each patient in the UFH group was matched to two patients in the LMWH group to the nearest fifth decimal point, utilizing a nearest neighbor schema. The matched cohort was evaluated for potential differences in confounding variables, and logistic or multivariable negative binomial linear regression was used to evaluate any associations between treatment group and outcome variables.
All significance tests were two sided and a P-value less than 0.05 was considered significant.
Results
A total of 103 798 patients were identified from 566 hospitals across the USA, of which 75 321 (72.6%) patients received LMWH prophylaxis and 28 477 (27.4%) patients received UFH prophylaxis. Patients in the LMWH group received at least one dose of therapy on 84.6% of hospital Data presented as n (%). LMWH, low-molecular-weight heparin; UFH, unfractionated heparin.
days compared with 95.5% of hospital days in the UFH group (P < 0.001). After propensity matching, a total of 63 561 patients were included, with 42 343 (66.6%) patients included within the LMWH prophylaxis study group and 21 218 (33.3%) patients included within the UFH prophylaxis study group. Most of the patients meeting inclusion criteria had non-metastatic solid tumor disease, with a majority of these patients being white (73%) and greater than 65 years of age (60%) in each group (Table 1) . Acute respiratory failure, obesity, heart failure, renal failure and malnourishment occurred in greater than 10% of the total patient cohort ( Table 2) . Data presented as n (%). LMWH, low-molecular-weight heparin; UFH, unfractionated heparin. Data presented as n (%). LMWH, low-molecular-weight heparin; UFH, unfractionated heparin; VTE, venous thromboembolism; PE, pulmonary embolism; HIT, heparin-induced thrombocytopenia.
The majority of patients were admitted to urban (88%) non-teaching medical centers (53%). After propensity matching, there were no significant differences in patient demographics and treatment setting. All patient comorbidities were balanced, with the following exceptions: acute ischemic stroke, acute respiratory failure, renal failure and renal replacement therapy (Tables 1 and 2 ).
Efficacy
In the LMWH group, 94% of the patients received enoxaparin as their prophylactic agent, 3% received dalteparin and 3% received fondaparinux. After propensity score matching, in the overall cohort of critically ill patients with cancer, VTE occurred in 5.5% of patients in the UFH group and 5.32% in the LMWH prophylaxis group (P = 0.326) ( Table 3 ). In the overall propensitymatched cohort, there was a significant difference in rates of pulmonary embolism, with 0.70% in the LMWH group and 0.99% in the UFH group (P < 0.001). In both the unmatched and the matched cohorts, there were not significant differences in in-hospital mortality or the composite outcome of VTE or mortality. Given the unbalanced baseline covariates, the results of the efficacy outcomes were adjusted to account for: acute respiratory failure, renal failure, acute ischemic stroke and renal replacement therapy. No differences were seen in the predefined efficacy outcomes in either the unmatched or matched cohorts after adjustment. There were no significant differences between the two prophylaxis groups in occurrence of VTE in the lymphoma and metastatic disease subgroups. The subgroup analysis of the non-metastatic solid disease cohort showed significantly reduced rates of VTE in the LMWH group (4.27%) compared with the UFH group (4.84%) (P = 0.036). 
Adverse effects
After propensity matching, significant bleeding events occurred in 13.29% of patients in the LMWH group and in 14.84% of patients in the UFH therapy group (P = < 0.001). The results of the adverse effects outcomes were adjusted to account for the unbalanced baseline covariates of acute respiratory failure, renal failure, acute ischemic stroke and renal replacement therapy. No differences were seen in the predefined adverse effects outcomes in either the unmatched or matched cohorts after adjustment. This reduction of significant bleeding events in the LMWH prophylaxis group was not seen in the lymphoma subgroup (11.18% vs. 12.35%, P = 0.189), but was seen in both the non-metastatic solid tumor disease subgroup (13.48% vs. 15.04%, P =< 0.001) and the metastatic disease subgroup (13.52% vs. 15.16%, P =< 0.001) ( Table 3 ). The incidence of HIT within the overall propensity-matched cohort was significantly lower in the LMWH prophylaxis group at 0.06% compared with 0.19% in the UFH prophylaxis group (P =< 0.001).
Multivariable analysis
The total cohort of 103 798 patients and the propensitymatched cohort of 63 561 patients were analyzed after adjusting for cancer cohort type, prophylactic therapy, VTE occurrence during admission, significant bleeding event during admission and patient comorbidities. In this analysis, treatment with LMWH was not associated with a reduced incidence of mortality (OR, 1.052; 95% CI, 0.989-1.12; P = 0.109) ( Table 4) . LMWH therapy was associated with a reduction in length of stay in the ICU (0.12 days; 95% CI, 0.04-0.20; P = 0.005) ( Table 5 ), but was not associated with a reduction in the overall length of stay in hospital (0.12 days; 95% CI, À0.02 to 0.25; P = 0.089) ( Table 6 ).
Discussion
The primary finding was that the selection of LMWHs for VTE prophylaxis in critically ill patients with cancer was not associated with a significant reduction of newonset inpatient VTE rates compared with the use of UFH prophylaxis. Despite the lack of association with use of LMWHs and the overall reduction of in-hospital VTE, there was a significant reduction in PE in the overall cohort. These results are consistent with a recently published prospective randomized controlled trial evaluating dalteparin prophylaxis and UFH prophylaxis in critically ill patients, which found no differences in their primary endpoint of rate of proximal leg DVT [9] . The rate of VTE observed in the aforementioned prospectively evaluated study (9.1%) is higher than the rate of VTE of 5.4% found in our cohort of critically ill patients with cancer. The difference in reported VTE rates is likely to be a result of preemptive screening methods used for VTE identification in the prospective trial, rather than charted ICD-9 codes. This lower rate of VTE may have impaired our ability to detect significant differences in rates of VTE between the treatment groups. Long-term outcomes in patients with and without cancer who develop VTE are poor, with high mortality rates [3, 5, 6] . The retrospective nature of this study may have prevented the detection of all VTE events, particularly subclinical DVTs and PEs. Our study suggests there is a significant reduction of VTE incidence in patients with non-metastatic solid tumor disease when LMWHs are used for VTE prophylaxis. This group is likely to benefit more than the other groups because of increased presence of inflammatory and cytokinergic molecules on solid tumors compared with lymphomas [18] . Additionally, the metastatic disease group included both patients with a primary cancer of solid tumors and those with lymphomas, increasing the heterogeneity and possibly diluting the thromboembolic effects of primary solid tumor metastases. Many solid tumor malignancies, such as pancreatic, brain and uterine, carry an increased risk of VTE compared with other types of malignancy [19] . LMWH prophylaxis may provide a more consistent reduction in VTE risk in these higher-risk groups. Currently, prospective research is needed to evaluate the true comparative effects of LMWHs vs. UFH on VTE rates in critically ill patients with cancer, as no such data exist. In our study, the use of LMWHs for VTE prophylaxis was associated with a significant reduction in the rate of bleeding events and HIT. These data mirror data from elective surgery patients with cancer showing trends toward decreased rates of significant bleeding [13] [14] [15] . The significant reduction in HIT found in our study is also similar to current data [20] . Our study reinforces the findings from a variety of clinical settings that LMWH prophylaxis reduces the proportion of patients with a significant bleeding event when compared with UFH and has a reduced rate of HIT [20, 21] . The significant reduction in bleeding may be because of the more consistent pharmacokinetic and dynamic properties demonstrated by LMWHs when compared with UFH [7, 22] . Our secondary analysis showed approximately a 2% significant reduction in significant bleeding in the metastatic and non-metastatic disease subgroups, but no significant difference was seen in the lymphoma subgroup. Although the numerical rate of significant bleeds was similar between the three groups, the non-metastatic solid disease group had significantly more patients and therefore had increased power to detect associations between the treatment groups. Further prospective research is needed to evaluate which patients may have the greatest significant bleeding risk reduction through treatment with LMWH therapy.
Several limitations need to be considered when interpreting the results of our study. Laboratory parameters (e.g. hemoglobin and histology), chemotherapy regimens, time from cancer diagnosis and cancer staging are not recoded within the Premier Database and were therefore not available for analysis. We were unable to adjust for confounding factors such as malignancy staging, outpatient VTE prophylaxis regimens, previous inferior vena cava filter placement or previously administered chemotherapy regimens. Patients who stayed in the hospital for ≤ 2 days were not included in the analysis, so patients with early mortality or less severe illness with early discharge were not evaluated. We were only able to determine associations between pharmacologic VTE prophylaxis therapy and patient outcomes, and cannot determine causality. Despite our rigorous statistical approach, the retrospective nature of this study limited our ability to completely mitigate potential prescriber bias and confounding by indication. The inability to control for clinical decision making within the statistical model may introduce potential baseline bias between possible high versus low-risk patients within the treatment group. This study was limited to patients included within the Premier Database and the patient populations seen at the included institutions. Therefore, there were significant differences in patients evaluated between the three cancer subgroup types. This restricted the power to identify significant associations within the lymphoma and metastatic disease groups compared with the non-metastatic sold disease subgroup. Although statistically significant differences were found in several of the secondary and subgroup analyses, the absolute differences seen are small. Providers should use clinical judgement when interpreting and applying the results of this population database approach to clinical practice.
Conclusion
Among critically ill patients with cancer admitted to the ICU, LMWHs, as compared with UFH, did not decrease the incidence of clinically relevant VTE. Low-molecularweight heparins were associated with a significant reduction in PEs in this patient population. A secondary analysis showed significantly reduced rates of VTE in patients with non-metastatic solid tumor disease treated with LMWHs as compared with UFH. There were significant reductions in the secondary endpoints of significant bleeding events and HIT in patients treated with LMWHs compared with UFH.
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